F7Trauma1648 - PowerPoint PPT Presentation

1 / 13
About This Presentation
Title:

F7Trauma1648

Description:

Total body surface area burns: 2 3 40 % (evaluated by the investigator ... extent of burns) Known or suspected pregnancy. Exclusion criteria continued ... – PowerPoint PPT presentation

Number of Views:25
Avg rating:3.0/5.0
Slides: 14
Provided by: christi468
Category:

less

Transcript and Presenter's Notes

Title: F7Trauma1648


1
F7Trauma-1648
  • Overview

2
Objective
  • To evaluate the efficacy and safety of rFVIIa
    (NovoSeven/ NiaStase) compared to placebo as an
    adjunct to standard treatment of trauma patients
    with active torso hemorrhage refractory to blood
    component therapy and surgical hemostatic
    procedures.

3
Inclusion criteria
  • Informed consent obtained before any trial
    related activities
  • Blunt and or penetrating trauma injury with
    evidence of active torso hemorrhage refractory to
    blood component therapy and surgical hemostatic
    procedures (proximal to the inguinal creases,
    proximal/medial to the axilla.

4
Inclusion criteria, continued
  • Evidence of active torso hemorrhage as defined
    as
  • Presence of acidosis (lactate gt6mmol/L(2
    times the local upper limit of normal-4.4) or
    Base Deficit 5mEq/L)
  • OR
  • Presence of hypotension (SBP 90 mmHg)
  • OR

5
Inclusion criteria continued
  • Presence of ongoing volume loading at a
    minimal rate of 1L/h (RBC or any other IV
    fluid/blood product and with continuing similar
    or greater need per the investigators judgment)
  • Receipt of a minimum of 4 units of RBC and the
    ability to administer study drug as soon as
    possible

6
Inclusion criteria continued
  • Upon completion of the 4th unit and before
    the completion of the 8th unit of blood.
  • Male or female patients, between 18-65 years of
    age or of legal age to consent per local law.

7
Exclusion criteria
  • Known age of lt18 or gt65 years of age or not of
    legal age to consent to participation in an
    investigational drug trial according to local
    law.
  • Moribund as defined by
  • pH 7.1 OR
  • SBP 50 mmHg or use of repeated bolus vasopressor
    treatment to support the blood pressure prior to
    randomization (bolus vasopressor use for reasons
    other than hypovolemia (i.e. spinal cord injury,
    anesthetic induction) does not exclude patient. OR

8
Exclusion criteria continued
  • Moribund as defined by (cont.)
  • Base Deficit (BD) gt 15 mEqL/ OR
  • Lactate gt 15 mmol/L OR
  • Anatomical injury incompatible with life (e.g.
    multiple cardiac wounds, unrepairable liver or
    pelvic injury) OR
  • Glascow Coma Scale (GCS) score never gt 5 at any
    time between injury and randomization in patients
    with any type of injury OR
  • Cardiac arrest any time from injury prior to
    randomization

9
Exclusion criteria continued
  • Evidence of head injury and suspicion of SEVERE
    brain trauma defined as any of the following
  • GCS8 and cranial CT showing AIS gt 3 OR
  • Abnormal physical exam (e.g. decorticate
    posturing) indicating brain injury OR
  • Intracranial injury AIS gt 3 on CT

10
Exclusion criteria continued
  • Time of injury to randomization gt 12 hours
  • Estimated time from injury to trial hospital
    admission gt 4 hours
  • Primary bleeding source localized to the
    extremities as per the investigators judgment
  • Treatment with aprotinin and aPCC or intention to
    treat with aprotinin and aPCC from injury thru
    day 5

11
Exclusion criteria continued
  • Known history of thromboembolic events within 30
    days
  • Presence of spinal cord injury above T6 with
    paralysis
  • Total body surface area burns 2 3 40
    (evaluated by the investigator using Lund-Browder
    chart for est. extent of burns)
  • Known or suspected pregnancy

12
Exclusion criteria continued
  • Previous randomization in this trial
  • Known part. in investigational/device trial
    within last 30 days
  • Estimated body weight lt 43 kg
  • Known or suspected allergy to trial product or
    related products
  • Known presence of congenital bleeding disorder

13
Contact information
  • Jason Hoth, MD PI
  • Pager 806-3091
  • Bill Martin project manager
  • Pager 806-7021
  • Office 6-1659
  • Judy Smith study coordinator
  • Pager 806-7217
  • Office 6-6287
Write a Comment
User Comments (0)
About PowerShow.com